Peripartum Cardiomyopathy in Nigeria Registry

Peripartum Cardiomyopathy Clinical Trial

— PEACE  

Official title:

Peripartum Cardiomyopathy in Nigeria (PEACE) A Registry to Study the Demographics, Social and Clinical Characteristics, Pathophysiology and Outcomes of Peripartum Cardiomyopathy in Nigeria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03081949
• Other study ID #: version 3
• Status: Completed
• Phase: Phase 4
• Start date: June 12, 2017
• Est. completion date: December 31, 2019

Study information

• Verified date: January 2021
• Source: Aminu Kano Teaching Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Peripartum cardiomyopathy (PPCM) is a global disease with significant morbidity and mortality, and Nigeria probably has the highest burden of the disease in the world. Unfortunately, much about the disease including its aetiology, epidemiology and treatment is not yet well described. This will be a prospective, national, multicenter cohort study, conducted in centres in Nigeria. It is expected that approximately 500 patients with PPCM and 500 apparently healthy pregnant women will be recruited over a 6-month period with follow-up at 3-monthly intervals for 18 months.

Description:

Peripartum cardiomyopathy (PPCM) is a global disease with significant morbidity and mortality, and Nigeria probably has the highest burden of the disease in the world. Unfortunately, much about the disease including its aetiology, epidemiology and treatment is not yet well described. This will be a prospective, national, multicenter cohort study, conducted in centres in Nigeria. It is expected that approximately 500 patients with PPCM and 500 apparently healthy pregnant women will be recruited over a 6-month period with follow-up at 3-monthly intervals for 18 months. The objectives of the study are: i. To describe the burden and demographic, social and clinical characteristics of PPCM in Nigeria. ii. To describe the ventricular remodelling and outcomes (rehospitalisation rate, cardio-embolic events and survival) of PPCM in Nigeria. Sub-study: iii. To study the relationship between selenium deficiency, oxidative stress and PPCM in Nigeria. iv. To describe the prevalence of selenium deficiency and its relationship with cardiac function in apparently healthy pregnant women in Nigeria. v. To study the impact of sodium selenite supplementation on cardiac function among selenium deficient PPCM patients who have not recovered left ventricular function at 6 months after the diagnosis. This will be the largest systematic evaluation of PPCM in Nigeria, and it is hoped that the information will assist in developing locally applicable treatment guidelines, policies and interventions for this seemingly deadly disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 31, 2019
• Est. primary completion date: June 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of PPCM
• PPCM patients with HF symptoms at the time of recruitment
• Asymptomatic pregnant women attending antenatal clinic (ANC)
• Sub-study: Open-label randomised Trial: Non-pregnant PPCM patients with all of the following: LVEF <35% and/or LVEDDi=33.0 mm/m2 at 6 months postpartum AND selenium deficiency
• Written informed consent

Exclusion Criteria:

• Asymptomatic PPCM patients at the time of recruitment
• PPCM patients who are not expected to survive at least 6 months from recruitment
• Pregnant women with any medical condition other than PPCM
• Subjects who are considered not likely to attend follow up reviews regularly, because of lack of patient's and close relative's phone numbers, or long distance from the study centre, etc
• Refusal or withdrawal of consent

Related Conditions & MeSH terms

• Cardiomyopathies
• Peripartum Cardiomyopathy

Intervention

Drug:
• Oral Sodium Selenite 200 µg/day for 3 months
PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) =33.0 mm/m2) at 6 months after diagnosis.

Locations

Country	Name	City	State
Nigeria	Aminu Kano Teaching Hospital	Kano
Nigeria	Aminu Kano Teaching Hospital	Kano

Sponsors (2)

Lead Sponsor	Collaborator
Aminu Kano Teaching Hospital	Nigerian Cardiac Society

Country where clinical trial is conducted

Nigeria, 

References & Publications (2)

Karaye KM, Sa'idu H, Balarabe SA, Ishaq NA, Sanni B, Abubakar H, Mohammed BL, Abdulsalam T, Tukur J, Mohammed IY. Correction to: Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial. BMC Cardiovasc Disord. 2021 Jan — View Citation

Karaye KM, Sa'idu H, Balarabe SA, Ishaq NA, Sanni B, Abubakar H, Mohammed BL, Abdulsalam T, Tukur J, Mohammed IY. Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial. BMC Cardiovasc Disord. 2020 Oct 21;20(1):457. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of peripartum cardiomyopathy (PPCM) in Nigeria	All participants confirmed to have PPCM presenting to the study centres, as described in PEACE Registry protocol V3.	Over 6 months
Secondary	Selenium deficiency in PPCM patients and apparently healthy pregnant women in Nigeria	Prevalence of selenium deficiency will be assessed. Serum selenium will be measured as described in PEACE Registry protocol V3. Selenium deficiency will be defined as serum selenium <70µg/L.	At baseline, 3 months, 12 and 18 months of follow up.
Secondary	Oxidative stress in PPCM patients and apparently healthy pregnant women in Nigeria	Prevalence of oxidative stress will be assessed. Serum malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidise (GPO) and N-terminal pro-B-type natriuretic peptide (NT-BNP) will be measured as described in PEACE Registry protocol V3. Abnormal oxidative stress will be defined as the presence of serum NT-BNP >125pg/mL and ANY of the following: plasma MDA >1.25µmol/L, serum SOD >110ng/mL and plasma GPO >470U/L.	At baseline, 3 months, 12 and 18 months of follow up.
Secondary	The effect of sodium selenite supplementation on cardiac function among PPCM patients.	PPCM patients with selenium deficiency, left ventricular ejection fraction (LVEF) <35% and/or insignificant left ventricular reverse remodeling (LVRR) at 6 months postpartum, will be offered sodium selenite 200mcg daily for 3 months, in an open-label randomized trial. LVRR would be defined as the presence of both absolute increase in LVEF =10.0% and decrease in LV end-diastolic dimension indexed to body surface area (LVEDDi) =33.0 mm/m2, while recovered LV systolic function as LVEF =55%, during the follow-up.; Change in LVEF and LVEDDi will be measured at 6, 12, and 18 months follow up visits, to determine prevalence of LVRR among partipants on selenium treatment and those who will not be on selenium treatment.	18 months
Secondary	Left Ventricular remodelling in PPCM patients	Change in LVEF and LVEDDi to determine LVRR	At baseline, and 6, 12 and18 months follow up
Secondary	Right Ventricular (RV) remodelling in PPCM patients	Change in RV fractional area change (RVFAC) of the right ventricle (in cm2), to determine RV reverse remodelling (RVRR). RVRR is defined as RVFAC >35cm2.	At baseline, and 6, 12 and18 months follow up
Secondary	Rehospitalisation rate	Number of participants who experience hospitalization for any cardiovascular disease during follow up.	18 months
Secondary	Prevalence of cardio-embolic events	Number of participants who experience stroke, transient ischemic attack or any gangrene during the follow-up period of the study.	18 months
Secondary	Survival rate	Number of participants who have survived the follow-up period of the study.	18 months